| Phase 4 |
| NCT01896479 |
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic… |
Medullary Thyroid Cancer |
Active, Not Recruiting |
2025-09-02 |
| Phase 3 |
| NCT07750158 |
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in… |
Colorectal Cancer |
Not Yet Recruiting |
2026-08-25 |
| NCT07620574 |
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… |
Cancer |
Enrolling by Invitation |
2026-08-18 |
| NCT05678673 |
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear… |
Non-Clear Cell Renal Cell Carcinoma |
Active, Not Recruiting |
2026-07-29 |
| NCT05425940 |
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal… |
Colorectal Cancer |
Active, Not Recruiting |
2026-07-17 |
| NCT04446117 |
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With… |
Metastatic Prostate Cancer |
Active, Not Recruiting |
2025-12-18 |
| NCT03755791 |
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants… |
Hepatocellular Carcinoma |
Active, Not Recruiting |
2025-12-11 |
| NCT03690388 |
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory… |
Differentiated Thyroid Cancer |
Active, Not Recruiting |
2025-09-25 |
| NCT03937219 |
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With… |
Renal Cell Carcinoma |
Active, Not Recruiting |
2025-09-10 |
| Phase 2/3 |
| NCT06943755 |
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic… |
Pancreatic Neuroendocrine Tumor (pNET) |
Recruiting |
2026-08-26 |
| NCT06082167 |
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1… |
Head and Neck Squamous Cell Carcinoma |
Active, Not Recruiting |
2025-08-17 |
| Phase 2 |
| NCT07428616 |
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma |
Meningioma |
Recruiting |
2026-07-27 |
| Phase 1 |
| NCT05176483 |
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in… |
Renal Cell Carcinoma (RCC) |
Recruiting |
2026-08-05 |
| NCT06952010 |
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With… |
Solid Tumor |
Recruiting |
2026-06-24 |
| NCT06545331 |
Study of XB010 in Subjects With Solid Tumors |
Locally Advanced or Metastatic Solid Tumors |
Recruiting |
2026-06-22 |
| NCT07123103 |
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid… |
Solid Tumors |
Recruiting |
2026-02-17 |
| NCT05932862 |
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced… |
Advanced Solid Tumor |
Recruiting |
2025-09-05 |
| NCT06962332 |
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic… |
Hepatic Impairment |
Recruiting |
2025-06-22 |
| NCT07773454 |
Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid… |
Cancer |
Not Yet Recruiting |
2026-08-19 |
| NCT03170960 |
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally… |
Urothelial Carcinoma |
Active, Not Recruiting |
2025-08-17 |
| NCT03845166 |
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors |
Neoplasm Malignant |
Active, Not Recruiting |
2024-11-19 |